ASTRO 2017: Perineural Invasion in Head and Neck Cancer

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights an education session on the challenge of perineural invasion in head and neck cancer from the 2017 ASTRO Annual Meeting.

In this video, Richard Bakst, MD, of the Icahn School of Medicine at Mount Sinai in New York, reviews highlights of an education session on the challenge of perineural invasion in head and neck cancer from the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held last month in San Diego.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Related Content
Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer

Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer

Ariana Pelosci
June 1st 2025
Article

Results from the NIVOPOSTOP trial found improved DFS with adjuvant nivolumab plus cisplatin and RT for patients with LA-SCCHN.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Efti plus pembrolizumab demonstrated no new safety signals in the TACTI-003 trial.

Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC

Russ Conroy
May 8th 2025
Article

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.

Event-free survival events were observed in 37.5% of patients taking pembrolizumab vs 45.3% without among patients with resectable locally advanced HNSCC.

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

Ashley Chan
April 30th 2025
Article

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma

Roman Fabbricatore
April 24th 2025
Article

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Vidya G Doddawad, BDS, MDS;B.M. Gurupadayya;Vidya CS;Shivananda S, BDS, MDS;Karthikeya Patil;R. Sumukh Bharadwaj
April 16th 2025
Article

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.